First trimester human umbilical cord perivascular cells (FTM HUCPVCs) expanded with cGMP compliant human platelet outperform conventional and older MSC sources as regenerative therapy in a rat myocardial infarction (MI) model

      FTM HUCPVCs are a novel potential source of young, immunoprivileged MSCs. We have shown that FTM HUCPVCs demonstrate significant homing, angiogenic and tissue remodelling capacities; characteristics crucial for the successful treatment of ischemic cardiac injury. This project therefore sought to identify the therapeutic potential of cGMP compliant FTM HUCPVCs, expanded for the preclinical and clinical treatment of MI.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect